Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
210 participants
INTERVENTIONAL
2026-02-01
2027-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Recent research suggests that disruptions in the body's autonomic nervous system, specifically the balance between the sympathetic and parasympathetic systems, play a role in the development of preeclampsia. The vagus nerve, which is part of the parasympathetic system, has been shown to regulate inflammation and blood pressure. Stimulating this nerve through pharmacological, magnetic, electrical, or physical therapy techniques has shown promise in preclinical models for improving blood pressure control and reducing complications associated with preeclampsia.
Trigger point release therapy modulates the nervous system by reducing sympathetic activity, promoting blood vessel relaxation, lowering heart rate, and enhancing circulation. When combined with standard antihypertensive treatment, this approach may offer additional benefits for blood pressure regulation.
This study aims to evaluate the effects of vagal autonomic stimulation physiotherapy using trigger point release therapy as a complementary treatment for pregnant women with preeclampsia. Participants will be randomly assigned to receive either standard antihypertensive treatment with positional release therapy (control group) or the same treatment combined with vagal stimulation physiotherapy (intervention group). Researchers will assess the intervention's effectiveness in controlling blood pressure and improving overall maternal and fetal health outcomes.
By investigating this non-invasive, drug-free approach, this study aims to offer new strategies for managing preeclampsia, potentially improving maternal and fetal health while reducing reliance on medication.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Physical Therapy in Pregnant Women With Preeclampsia
NCT01630772
Leg Heating in Pregnant Women With Obesity
NCT06932250
Prenatal Yoga as Complementary Therapy of Preeclampsia
NCT04795154
Optic Nerve Sheath Measurement and Angiogenic Factors in Patients With Pre-eclampsia.
NCT06122220
Treatment Approaches to Preeclampsia
NCT01030627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Although its global prevalence is unknown, preeclampsia is implicated in 14% of maternal deaths worldwide. In Mexico, it accounts for approximately 14% of maternal mortality, corresponding to a rate of 30.4 per 100,000 live births, and 17.2% of total perinatal deaths. Of these maternal deaths, 30% to 70% result from neurological complications where cerebral autoregulation is lost, leading to vasospasm, reduced blood flow, and ischemic and infarcted areas in the placenta.
Recent evidence suggests that dysregulation of the cholinergic anti-inflammatory pathway (CAP) may contribute to preeclampsia development. This pathway connects the central nervous system-via the vagus nerve-to mechanisms regulating inflammation in the body. It is influenced by the downregulation of the α7 nicotinic acetylcholine receptor, which has been associated with systemic inflammation in preeclampsia. Additionally, some electrical, pharmacological, magnetic, and physical vagal stimulation techniques targeting this pathway have shown promising results in preclinical models of preeclampsia, making vagus nerve activation a potential strategy for managing this pregnancy complication. Clinically, various vagal stimulation techniques, such as deep breathing, progressive relaxation, and transcranial magnetic stimulation, have been approved for treating depression and epilepsy in pregnant women.
Primarily linked to the parasympathetic nervous system, the vagus nerve is also influenced by the sympathetic nervous system through peripheral receptors. Trigger point stimulation therapy in physiotherapy can block sympathetic nervous system activity, reducing peripheral vascular resistance, venous return, heart rate, and myocardial contractility by promoting systemic arterial and venous vasodilation. In this context, physiotherapy involving trigger point release could serve as an adjunct treatment for blood pressure control in preeclamptic patients by modulating the peripheral nervous system. However, its impact on autonomic tone has not yet been reported.
This study aims to explore the benefits of vagal stimulation through trigger point release, combined with medical treatment for preeclampsia-an approach that has not been fully investigated in our setting. This protocol presents a non-invasive complementary technique to support personalized pharmacological management of preeclamptic patients. By enhancing the vasorelaxant response derived from autonomic nervous system activity, this intervention may help reduce blood pressure levels and biochemical markers associated with preeclampsia.
Objective: To determine the effect of vagal autonomic stimulation physiotherapy with trigger point release on hemodynamic control compared to positional release therapy as adjuvant treatments in personalized antihypertensive therapy for gestational hypertension syndrome preeclampsia.
Methods: This is an Experimental, randomized, double-blind, parallel-group clinical trial with an open-label intervention administration, with a control group (2:1 ratio), designed to assess the effectiveness of vagal stimulation physiotherapy with trigger point release as an adjuvant treatment for mild preeclampsia in pregnant women. The study will be conducted over 12 months at several hospitals of the Mexican Institute of Social Security.
Participants:
Women over 18, beneficiaries of the Mexican Institute of Social Security (IMSS), diagnosed with mild preeclampsia, will be randomly assigned to one of two groups:
1. Intervention group: Receives vagal stimulation physiotherapy with trigger point release every two weeks, along with personalized antihypertensive treatment.
2. Control group: Receives positional release therapy every two weeks, along with personalized antihypertensive treatment.
Study Design:
* Blinding: Double-blind (patients and researcher performing statistical analysis).
* Sample Size: 210 patients (147 in the experimental group, 63 in the control group).
* Randomization: Block randomization generated by computer.
Inclusion Criteria: Outpatient pregnant women aged 18 years or older who are attending their first obstetrics consultation at the Regional General Hospitals of IMSS Jalisco with a confirmed diagnosis of mild preeclampsia. Participants must have no prior antihypertensive treatment and must be willing to participate by signing an informed consent form.
Exclusion Criteria: Patients with chronic hypertension, concomitant organ dysfunction, or immunological diseases will be excluded from the study. Additionally, those with severe preeclampsia or any chronic condition complicating pregnancy will not be eligible. Patients diagnosed with gestational trophoblastic disease requiring uterine evacuation or choriocarcinoma will also be excluded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vagal Stimulation Physiotherapy with Trigger Point Release (TEV Group).
Administration of physiotherapy sessions for vagal stimulation with trigger point release, in addition to personalized antihypertensive treatment.
Vagal stimulation physiotherapy with trigger point release
The patient will be instructed to remain in a seated position, with the knee slightly ahead of the feet and the feet firmly planted on the floor, with the hips higher than the knees. The therapist will stand behind the patient. Myofascial release will be performed on the upper trapezius (UT) while the patient slowly turns their head from side to side and lets it drop forward. The therapist will then apply pressure on the opposite side of the rotation.
* Therapist's position: Behind the patient.
* Patient's position: Seated with the spine in a neutral position.
Positional Release Therapy (TLP Group).
Administration of positional release therapy sessions, in addition to personalized antihypertensive treatment.
Positional Release Therapy
A 30-minute session of positional release therapy will be provided every two weeks, in addition to personalized antihypertensive treatment, from the start of treatment (T0) until the final measurement (days 28 to 35 after obstetric resolution).
Keeping the cervical spine in a neutral position, the participant will be asked to lie down in a relaxed supine position. The therapist will progressively apply more pressure to the trigger points identified with their thumb. In the next step, the therapist will move to a more comfortable position that exerts less stress. The therapist will passively hold the patient's upper limbs in an abducted position, with a rest period between each repetition.
* Therapist's position: On the side of the patient.
* Patient's position: Supine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vagal stimulation physiotherapy with trigger point release
The patient will be instructed to remain in a seated position, with the knee slightly ahead of the feet and the feet firmly planted on the floor, with the hips higher than the knees. The therapist will stand behind the patient. Myofascial release will be performed on the upper trapezius (UT) while the patient slowly turns their head from side to side and lets it drop forward. The therapist will then apply pressure on the opposite side of the rotation.
* Therapist's position: Behind the patient.
* Patient's position: Seated with the spine in a neutral position.
Positional Release Therapy
A 30-minute session of positional release therapy will be provided every two weeks, in addition to personalized antihypertensive treatment, from the start of treatment (T0) until the final measurement (days 28 to 35 after obstetric resolution).
Keeping the cervical spine in a neutral position, the participant will be asked to lie down in a relaxed supine position. The therapist will progressively apply more pressure to the trigger points identified with their thumb. In the next step, the therapist will move to a more comfortable position that exerts less stress. The therapist will passively hold the patient's upper limbs in an abducted position, with a rest period between each repetition.
* Therapist's position: On the side of the patient.
* Patient's position: Supine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No prior treatment.
* Willing to participate by signing an informed consent form.
Exclusion Criteria
* Concomitant organ dysfunction.
* Immunological diseases.
* Patients with severe preeclampsia or chronic conditions concomitant with pregnancy.
* Patients with gestational trophoblastic disease requiring uterine evacuation or choriocarcinoma associated with hypertension.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Coordinación de Investigación en Salud, Mexico
OTHER_GOV
Fundación Internacional René Mey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Carlos Alberto Garcia Becerra
Principal Investigator, Fundación Internacional René Mey
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luz Ma. Adriana Balderas-Peña, Ph.D.
Role: STUDY_CHAIR
Unidad de Investigación Biomédica 02, UMAE HE CMNO IMSS
René Jaques Mey, Dr. h.c.
Role: PRINCIPAL_INVESTIGATOR
Fundación Internacional René Mey
Juliette Myriam Laure, M.Sc.
Role: PRINCIPAL_INVESTIGATOR
Fundación Internacional René Mey
Carlos A. García-Becerra, M.Sc.
Role: PRINCIPAL_INVESTIGATOR
Fundación Internacional René Mey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unidad de Investigación Biomédica 02, UMAE HE CMNO IMSS
Guadalajara, Jalisco, Mexico
Hospital General de Zona 110, IMSS
Guadalajara, Jalisco, Mexico
Hospital General de Zona 46, IMSS
Guadalajara, Jalisco, Mexico
Hospital General de Zona 180, IMSS
Tlajomulco de Zúñiga, Jalisco, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R-2025-785-018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.